Hydrogen sulfide's role in preventing glioblastoma growth
Official title: Hydrogen sulfide functions as a tumor suppressor in glioblastoma
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11042844 · Data updated 2026-11-12
This study is looking at how hydrogen sulfide might help fight glioblastoma, a tough type of brain cancer, especially in older patients, and it explores ways to change hydrogen sulfide levels through diet or medication to find new treatments for this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | April 1, 2023 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $515,147 |
| NIH project number | 5R01NS127374-03 |
| Project ID | NIH-11042844 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 65 and older who are diagnosed with glioblastoma.
✕Less likely to help
Patients under the age of 65 or those without a diagnosis of glioblastoma may not benefit from this research.
What this research studies
This research investigates how hydrogen sulfide (H2S) can act as a tumor suppressor in glioblastoma, the most common malignant brain tumor in adults. The study focuses on understanding the effects of advanced age on cancer stem cells and how H2S influences their maintenance and tumor growth. By exploring dietary and pharmacological methods to modulate H2S levels, the research aims to uncover new therapeutic strategies for glioblastoma treatment. Patients may be involved in trials assessing these interventions and their impact on tumor progression.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that effectively slow down or prevent the growth of glioblastoma in patients.
How similar studies have gone: While the role of hydrogen sulfide in cancer is being explored, this specific approach in glioblastoma is relatively novel and has not been extensively tested.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Hine, Christopher Michael — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Hine, Christopher Michael
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.